Liao Chi-chou says that the reason Taiwan carries out so few Phase 1 trials is that Phase 1 trials are very small. Because they typically involve only 20-80 people, most drug companies simply carry them out wherever they happen to have developed the drug.
藥政處長廖繼洲認為，台灣第一期臨床試驗數偏低的原因在於──第一期試驗所需人數本來就少（20 ∼ 80 人），藥品開發公司多選擇在研發當地進行試驗即可。